200 related articles for article (PubMed ID: 17178722)
21. Polycythemia vera: scientific advances and current practice.
Tefferi A; Spivak JL
Semin Hematol; 2005 Oct; 42(4):206-20. PubMed ID: 16210034
[TBL] [Abstract][Full Text] [Related]
22. An inhibitor of Janus kinase 2 prevents polycythemia in mice.
Mathur A; Mo JR; Kraus M; O'Hare E; Sinclair P; Young J; Zhao S; Wang Y; Kopinja J; Qu X; Reilly J; Walker D; Xu L; Aleksandrowicz D; Marshall G; Scott ML; Kohl NE; Bachman E
Biochem Pharmacol; 2009 Aug; 78(4):382-9. PubMed ID: 19413997
[TBL] [Abstract][Full Text] [Related]
23. Characterization of murine JAK2V617F-positive myeloproliferative disease.
Bumm TG; Elsea C; Corbin AS; Loriaux M; Sherbenou D; Wood L; Deininger J; Silver RT; Druker BJ; Deininger MW
Cancer Res; 2006 Dec; 66(23):11156-65. PubMed ID: 17145859
[TBL] [Abstract][Full Text] [Related]
24. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
25. Dasatinib inhibits progenitor cell proliferation from polycythaemia vera.
Wappl M; Jaeger E; Streubel B; Gisslinger H; Schwarzinger I; Valent P; Oehler L
Eur J Clin Invest; 2008 Aug; 38(8):578-84. PubMed ID: 18717827
[TBL] [Abstract][Full Text] [Related]
26. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells.
Mullally A; Lane SW; Ball B; Megerdichian C; Okabe R; Al-Shahrour F; Paktinat M; Haydu JE; Housman E; Lord AM; Wernig G; Kharas MG; Mercher T; Kutok JL; Gilliland DG; Ebert BL
Cancer Cell; 2010 Jun; 17(6):584-96. PubMed ID: 20541703
[TBL] [Abstract][Full Text] [Related]
27. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
Zhan H; Spivak JL
Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
[TBL] [Abstract][Full Text] [Related]
28. The polycythemia vera-associated Jak2 V617F mutant induces tumorigenesis in nude mice.
Abe M; Funakoshi-Tago M; Tago K; Kamishimoto J; Aizu-Yokota E; Sonoda Y; Kasahara T
Int Immunopharmacol; 2009 Jul; 9(7-8):870-7. PubMed ID: 19327411
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.
Wernig G; Kharas MG; Okabe R; Moore SA; Leeman DS; Cullen DE; Gozo M; McDowell EP; Levine RL; Doukas J; Mak CC; Noronha G; Martin M; Ko YD; Lee BH; Soll RM; Tefferi A; Hood JD; Gilliland DG
Cancer Cell; 2008 Apr; 13(4):311-20. PubMed ID: 18394554
[TBL] [Abstract][Full Text] [Related]
30. Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera.
Ishii T; Bruno E; Hoffman R; Xu M
Blood; 2006 Nov; 108(9):3128-34. PubMed ID: 16757685
[TBL] [Abstract][Full Text] [Related]
31. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
Tutaeva V; Misurin AV; Michiels JJ; Rozenberg JM; Sokolova MA; Ivanova VL; Kolosheinova TI; Manakova TE; Levina AA; Semenova EA; Khoroshko ND
Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451
[TBL] [Abstract][Full Text] [Related]
32. Transcriptional profiling of polycythemia vera identifies gene expression patterns both dependent and independent from the action of JAK2V617F.
Berkofsky-Fessler W; Buzzai M; Kim MK; Fruchtman S; Najfeld V; Min DJ; Costa FF; Bischof JM; Soares MB; McConnell MJ; Zhang W; Levine R; Gilliland DG; Calogero R; Licht JD
Clin Cancer Res; 2010 Sep; 16(17):4339-52. PubMed ID: 20601445
[TBL] [Abstract][Full Text] [Related]
33. Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study.
Vannucchi AM; Verstovsek S; Guglielmelli P; Griesshammer M; Burn TC; Naim A; Paranagama D; Marker M; Gadbaw B; Kiladjian JJ
Ann Hematol; 2017 Jul; 96(7):1113-1120. PubMed ID: 28456851
[TBL] [Abstract][Full Text] [Related]
34. Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera.
Mullally A; Bruedigam C; Poveromo L; Heidel FH; Purdon A; Vu T; Austin R; Heckl D; Breyfogle LJ; Kuhn CP; Kalaitzidis D; Armstrong SA; Williams DA; Hill GR; Ebert BL; Lane SW
Blood; 2013 May; 121(18):3692-702. PubMed ID: 23487027
[TBL] [Abstract][Full Text] [Related]
35. In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele.
Gaikwad A; Nussenzveig R; Liu E; Gottshalk S; Chang K; Prchal JT
Exp Hematol; 2007 Apr; 35(4):587-95. PubMed ID: 17379069
[TBL] [Abstract][Full Text] [Related]
36. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.
Lacout C; Pisani DF; Tulliez M; Gachelin FM; Vainchenker W; Villeval JL
Blood; 2006 Sep; 108(5):1652-60. PubMed ID: 16670266
[TBL] [Abstract][Full Text] [Related]
37. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
[TBL] [Abstract][Full Text] [Related]
38. Polycythemia vera: the current status of preclinical models and therapeutic targets.
Bartalucci N; Guglielmelli P; Vannucchi AM
Expert Opin Ther Targets; 2020 Jul; 24(7):615-628. PubMed ID: 32366208
[TBL] [Abstract][Full Text] [Related]
39. The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F).
Guerini V; Barbui V; Spinelli O; Salvi A; Dellacasa C; Carobbio A; Introna M; Barbui T; Golay J; Rambaldi A
Leukemia; 2008 Apr; 22(4):740-7. PubMed ID: 18079739
[TBL] [Abstract][Full Text] [Related]
40. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]